America's Seed Fund: The SBIR Program and the Future of Biotech Innovation
For over four decades, the Small Business Innovation Research program has been the lifeblood of early-stage science in America — bridging the chasm between breakthrough discovery and viable therapy. Here's why it matters, what's at stake, and what comes next.
At UP Oncolytics, our mission — developing Zika virus as a precision oncologic agent against glioblastoma and other hard-to-treat cancers — sits squarely at the frontier of high-risk, high-reward science. It is precisely the kind of work that private capital alone would rarely fund in its earliest stages. That is why we, like thousands of other biotechnology startups across the country, look to one program above all others as the foundation of early-stage R&D financing: the Small Business Innovation Research (SBIR) program.
This post traces the origins, scale, and impact of that program, and addresses the turbulent reauthorization battle that recently placed it — and companies like ours — in an alarming state of limbo.
Origins: A Congressional Recognition of Small Business Innovation
The SBIR program was born out of a paradox. Congress recognized in 1982 that small businesses were "the principal source of significant innovations in the Nation," yet the overwhelming majority of federally funded research and development was being performed by large corporations, universities, and federal laboratories. Small companies — nimble, creative, willing to pursue ideas that no established player would touch — were systematically shut out of the federal R&D pipeline.
The Small Business Innovation Development Act of 1982 (P.L. 97-219) mandated that every federal agency with an extramural R&D budget exceeding $100 million must set aside a defined percentage of those funds to operate a competitive, merit-based small business R&D grant program.
The program was structured in three phases. Phase I provides seed funding to test the feasibility of a technology or therapeutic concept. Phase II supports deeper development for projects that pass Phase I scrutiny and demonstrate commercial potential. Phase III — funded by non-SBIR sources — bridges the gap to market. The design was deliberate: move ideas from hypothesis to product without the company surrendering equity, control, or scientific independence.
A companion program, the Small Business Technology Transfer (STTR) program, was added in 1992 to enable formal partnerships between small businesses and nonprofit research institutions — a structure particularly well suited to biotech startups whose science often emerges from academic laboratories.
Scale and Growth: Forty-Three Years of Investment
The numbers that have accumulated over four decades are extraordinary. Through fiscal year 2019, federal agencies had issued more than 178,731 awards totaling $54.6 billion in combined SBIR and STTR funding. By fiscal year 2022, annual SBIR obligations alone had grown to $4.4 billion, with the Department of Defense and the Department of Health and Human Services (which houses the NIH) together accounting for more than three-quarters of all awards.
The NIH's own small business programs have expanded considerably in recent years, growing from approximately $983 million in 2017 to $1.37 billion in 2023. For the life sciences and biotech communities, NIH SBIR and STTR grants represent one of the most important and accessible sources of non-dilutive early-stage capital in existence.
The SBIR and STTR programs together add an estimated 65,578 jobs to the U.S. economy annually, with awards distributed across all 50 states and U.S. territories.
Perhaps just as important as the dollar figures is the signal that SBIR awards transmit to the broader investment community. For a small biotech navigating the "valley of death" — the treacherous gap between compelling laboratory data and investable clinical assets — an SBIR award carries substantial validating weight. It signals that an independent panel of scientific reviewers has assessed the work as rigorous, innovative, and commercially relevant. Venture capitalists and strategic investors frequently cite SBIR status as a decision-making input.
A Timeline of Reauthorizations
Success Stories: From Grant to Blockbuster
The most compelling case for the SBIR program is not found in aggregate statistics, but in the specific companies and therapeutics it helped bring into existence. The program's track record in biotech and life sciences is remarkable.
Received seven SBIR awards in its first decade of operation. The company grew to become the third-largest biotechnology firm in the world before being acquired by Sanofi in 2011 for $20.1 billion.
A $1.5 million Phase II SBIR grant from the NIH in 2018 enabled acceleration of a novel bioabsorbable surgical clip toward commercialization at a moment when follow-on funding was uncertain.
Multiple Phase I, II, and Phase IIB awards from NSF's SBIR program supported a pipeline that launched six spin-off companies. For every $1 of SBIR funding received, Luna generated $2 in non-SBIR investment.
An NSF SBIR award provided the "stamp of approval" of a leading science agency, helping attract venture capital to accelerate development of breakthrough nanocomposite solar cell technology.
These are not outliers. They represent a pattern: SBIR funding de-risks early-stage innovation, attracts follow-on private investment, and creates the runway necessary for breakthrough science to mature into commercial reality.
NIH small business funding gave us the preliminary data that allowed us to approach investors and Big Pharma to fund the amount needed to move into phase two and phase three.
The 2025 Reauthorization Crisis
The program's most recent chapter has been its most turbulent. On September 30, 2025 — for the first time in recent memory without even a short-term stopgap in place — the statutory authority for the SBIR and STTR programs simply expired.
The breakdown was the product of a genuine ideological dispute about the program's future. Senator Joni Ernst (R-Iowa) had introduced the INNOVATE Act, which proposed sweeping reforms: a controversial $75 million lifetime cap on how much any single company could receive in SBIR funding, new "Phase IA" awards for first-time applicants, and structural changes aimed at pushing companies more aggressively toward commercial markets and away from what critics described as a "cottage industry" of perennial SBIR recipients. Senator Ernst and her allies argued that the program, designed for a 1982 R&D landscape, had grown poorly suited to 21st-century innovation ecosystems where the commercial sector now drives more technology development than the government.
On the other side, Senator Ed Markey (D-Massachusetts) and a broad coalition of small business advocates, research universities, and biotech stakeholders opposed the proposed caps as punitive to exactly the most productive SBIR participants. Companies that win repeated SBIR awards, they argued, are often doing so because they are performing sustained, cutting-edge research that requires years of federal support before reaching a commercial threshold.
The House passed a clean one-year extension — H.R. 5100 — on September 15, 2025, with unanimous, bipartisan support. When the measure reached the Senate floor under unanimous consent, a single objection was enough to halt it. That single objection came from Senator Ernst's office, and with it, the programs went dark on October 1.
During the five-month authorization gap, more than $4 billion in annual R&D funding across 11 federal agencies was frozen. New solicitations were suspended, Phase I and Phase II awards could not be issued, and companies dependent on anticipated renewals faced severe operational and hiring disruptions. Some small businesses did not survive the wait.
The human cost of the lapse was considerable. Small biotech startups — many operating on lean budgets with small teams — faced uncertainty about whether annual grant renewals would materialize. Hiring froze. R&D timelines slipped. The Space Force's Rapid Capabilities Office paused contracts for satellite communications and warning sensor programs due to the authorization gap, illustrating that the stakes extended well beyond the life sciences.
Resolution: The Small Business Innovation and Economic Security Act
On February 25, 2026 — after nearly five months of lapsed authority and what one advocate called "the longest authorization lapse in the programs' 42-year history" — Senators Ernst and Markey announced a bipartisan deal. The compromise legislation, the Small Business Innovation and Economic Security Act, was immediately hot-lined in the Senate, signaling leadership confidence that it could pass without triggering another objection.
The breakthrough reportedly came after Pentagon officials threatened to redirect SBIR-designated funds if Congress did not act, and provided assurances to Senator Markey about implementation of the compromise's most contentious provisions. The most divisive element of Senator Ernst's original proposal — the $75 million lifetime funding cap — was dropped entirely. In its place, the bill gives SBIR office directors at each federal agency the authority to set annual limits on the number of proposals any single company may submit, a more flexible and agency-appropriate mechanism.
The compromise also includes new "Strategic Breakthrough" awards, enhanced foreign influence provisions specifically targeting entities linked to the Chinese government, improved data collection requirements on commercialization outcomes, and reauthorization of all existing pilot programs — through September 30, 2031, providing five years of stability that the small business community has urgently needed.
The Small Business Innovation and Economic Security Act reauthorizes SBIR and STTR through September 30, 2031, eliminates the controversial $75M lifetime funding cap, introduces new Strategic Breakthrough awards, strengthens foreign-influence safeguards, and requires improved commercialization tracking. With Senate passage expected imminently and House passage to follow, the program's five-year runway is now within reach.
What This Means for UP Oncolytics — and the Field
For a company like ours, developing a novel oncolytic virus platform to treat glioblastoma, the restoration of SBIR authority cannot come soon enough. We are proud recipients of an NIH SBIR Fast Track award — a combined Phase I/II grant totaling approximately $2.3 million — which is directly funding our Zika virus oncolytic program. The Fast Track mechanism, which allows meritorious Phase I projects to apply for Phase II funding simultaneously and without interruption, is exactly the kind of streamlined, science-first support that enables a small team to move with the urgency that a disease like glioblastoma demands.
Our experience is a microcosm of the program's broader value proposition. Our science is exactly what SBIR was designed to support: high-risk, early-stage, paradigm-challenging research that private investors are unlikely to fund without substantial de-risking. The grant provides non-dilutive capital that allows us to generate the data needed to attract subsequent investment, partner with leading academic research institutions, and maintain the scientific independence necessary to pursue the biology where it leads — not where investor pressure demands.
The five-year reauthorization, if enacted as expected, also provides the planning horizon that early-stage biotechs genuinely need. Multi-year R&D programs cannot be built on programs that require existential lobbying fights every two or three years. The stability promised by the Small Business Innovation and Economic Security Act matters as much as the funding itself.
More broadly, the episode is a reminder of just how fragile the innovation ecosystem is, and how much depends on congressional stewardship of programs that most Americans have never heard of. The SBIR program does not generate the kind of political visibility that drives legislative action in most election cycles. Its beneficiaries are, by definition, small. But the aggregate output — the therapies developed, the technologies commercialized, the jobs created, the national security capabilities built — is enormous, and uniquely tied to the existence of this program as a sustained, reliable feature of the federal R&D landscape.
We are proud to be pursuing our work at this intersection of virology, oncology, and translational science, and we look forward to sharing more about our SBIR journey as it unfolds. The program has shaped the trajectories of some of the most important companies in the history of biotechnology. We intend to add UP Oncolytics to that list.
Regulatory Notice: The therapeutic approaches described herein are investigational. UP Oncolytics' ZIKV oncolytic therapy has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for the treatment of glioblastoma or any other condition. This content is for informational and educational purposes only and does not constitute medical advice.